Latest news with #Varian
Tokyo Weekender
26-05-2025
- Health
- Tokyo Weekender
The Central Japan International Medical Center Is Revolutionizing Cancer Care
Nestled in the heart of Japan , the brand-new Central Japan International Medical Center (CJIMC) stands as a beacon of excellence in global health care. With state-of-the-art facilities and highly advanced technology, coupled with an intense focus on quality of care, CJIMC is emerging as a premier destination for international patients seeking top-tier medical services in Asia. 'Having seen medical care from all over the world, I designed this medical center with a global approach, equipped to treat patients from all backgrounds. The facility is supposed to feel more like a hotel than a hospital,' explains Dr. Jitsuhiro Yamada, the chairperson of Central Japan International Medical Center and a past international president of Lions Clubs International. CJIMC caters to patients of all backgrounds and nationalities — among them, medical tourists who come to Japan specifically to access cutting-edge care at a comparatively low cost. The facility offers a wide variety of services, including comprehensive health screenings and checkups, but what perhaps stands out most is its Proton Therapy Center, which is home to one of the world's most advanced and innovative radiation oncology treatment systems. Varian ProBeam 360° Revolutionizing Cancer Care At the heart of CJIMC's Proton Therapy Center lies the Varian ProBeam 360°, a highly advanced proton therapy system made in the US . Unlike traditional radiation therapy (which uses X-ray and gamma ray particles), the ProBeam 360° uses a proton particle beam, which is able to accurately zero in on tumors; this allows for unparalleled precision in targeting cancerous cells while minimizing damage to surrounding healthy tissues, proving particularly effective for treating cancers in delicate locations. 'Cancer is the scariest diagnosis a patient can receive,' Dr. Yamada says. 'We've integrated the ProBeam 360°, a highly effective, third-generation proton therapy equipment.' This cutting-edge treatment is offered in very few locations worldwide. 'We're working hard to make it easier for international patients to receive cutting-edge cancer treatment here.' Dr. Jitsuhiro Yamada The Proton Therapy Center is led by Dr. Nobukazu Fuwa, one of Japan's most respected radiation oncology experts, and treatments are delivered on an outpatient basis. Each treatment session usually takes 10 to 15 minutes, meaning that patients spend just a fraction of their day in the hospital. Though it varies based on cancer type and severity, Dr. Yamada says that proton therapy can sometimes conclude in around 21 sessions — for example, in the case of prostate cancer — allowing patients to receive a full course of treatment in a single month. It's an especially appealing option given the high costs of healthcare in America. 'With proton therapy that uses the American-made Varian system, even after purchasing round-trip airfare to Japan and getting gifts for your family here, the total cost would still be lower than just receiving treatment in the US,' notes Dr. Yamada. Elmammo PET scanner A Leading Force in Preventive Medicine Beyond specialized treatment, CJIMC is also a hub for preventive care and comprehensive health screening. The hospital offers full-body checkup packages designed to detect health issues at their earliest, most treatable stages — including full-body cancer screenings, cardiovascular system screenings and brain screenings. As such, it's an ideal destination for health-conscious travelers seeking peace of mind. The full-body cancer screening course includes an MRI, blood testing and a PET/CT scan, a combined imaging test that shows both the metabolic activity and detailed anatomy of one's body. In America, PET scans can cost several thousand dollars, and insurance can refuse to cover the examination if it's deemed not medically necessary. CJIMC is also equipped with an Elmammo PET scanner, a PET imaging system dedicated exclusively to breast cancer detection. This groundbreaking technology delivers highly accurate results without the discomfort of traditional mammography, making it an extremely popular option for female patients. International Support and Accessibility Recognizing the increasing demand from international patients, CJIMC works with English-speaking coordinators to assist with every step, from scheduling and payment to medical interpretation and aftercare support. Patient privacy and comfort are a top priority, and the facility's staff work hard to ensure that every international visitor experiences seamless, compassionate and culturally sensitive care. Although some overseas visitors may not be familiar with Gifu, it's centrally located and easy to reach from any of Japan's major cities. Situated just over an hour from Chubu Centrair International Airport and within easy reach of Nagoya, the hospital is easily accessible by high-speed rail, expressway or plane. Moreover, Gifu's beautiful nature and rich cultural heritage offer a peaceful and restorative environment — ideal for recovery and rehabilitation. Patients can experience the tranquility of Japan's heartland while receiving world-class medical care. Inuyama Inuyama Culture, History and Natural Beauty The medical center is located in close proximity to a number of scenic and culturally rich locations, which patients can explore once their treatment has concluded. Among them is the picturesque mountain village of Shirakawa-go, a UNESCO World Heritage Site famed for its traditional gassho-zukuri thatched-roof farmhouses — an enchanting, fairy tale-esque view. Nearby, the Okuhida region beckons with its dramatic 3,000-meter-class peaks and a wealth of natural hot springs, perfect for relaxation and recovery. Access is convenient: It takes just about 1 hour and 40 minutes by express train from the medical center to Takayama Station, which serves as the gateway to all these areas. The town of Inuyama, which neighbors CJIMC, is also full of things to do. It's home to Inuyama Castle, one of the five national treasure castles in Japan alongside Himeji and Matsumoto castles. Its main keep offers panoramic views of the Kiso River. The area surrounding the castle retains its Edo-period charm, with narrow lanes lined with traditional merchant houses, quaint shops and local eateries. The castle town is domestically known for the Inuyama Festival in early April, where intricately decorated floats are paraded through the streets, illuminated by hundreds of lanterns. Museum Meiji-Mura Museum Meiji-Mura Just a short distance from the castle, Museum Meiji-Mura is an open-air museum showcasing over 60 culturally significant buildings from the Meiji era. Among its treasures is the reconstructed main entrance of Tokyo's old Imperial Hotel, designed by Frank Lloyd Wright. Visitors can explore historic structures, ride a steam locomotive and wander through all 100 hectares of the whimsical park-museum steeped in nostalgia and historical significance. Elevating Global Health Standards As the world becomes more interconnected, the need for trusted, globally accessible health care providers continues to grow. With its fusion of cutting-edge technology, medical expertise and patient-centered care, Central Japan International Medical Center is poised to become a global leader in modern medicine. Whether it's the quiet dignity of individualized care or the seamless integration of some of the world's most advanced medical innovations, CJIMC embodies the values that have long placed Japan at the forefront of health care globally. 'I always teach new doctors that the center of medicine is not the doctor, but the patient. Patients come to us troubled by illness, and it is our job as doctors to use our knowledge to support them,' says Dr. Yamada. More Info Central Japan International Medical Center 1-1 Kenkonomachi, Minokamo, Gifu 505-8510 T: +81 574-66-1100
Yahoo
15-05-2025
- Business
- Yahoo
Siemens Healthineers relocates Varian's Mexico manufacturing to the US
Siemens Healthineers has become the latest company to double-down on investment in the US amid ongoing tariff fallout, outlaying $150m to bring back manufacturing in the country from Mexico. The latest investment will see the Germany-headquartered giant relocate manufacturing operations for its subsidiary Varian from Baja, Mexico to Palo Alto, California. Siemens Healthineers, which employs 17,000 people in the US, said the move would add around 50 new jobs in the manufacturing of Varian's radiotherapy products. Siemens acquired Varian for $26.4bn in April 2021. Varian is known for making a range of devices involved in the cancer treatment space, such as linear accelerators, radiotherapy systems, and diagnostic software. The expansion to operations in the US, a country responsible for 36% of the company's global revenue, includes opening 'mega supply depots' in New Jersey and California to increase availability of device parts by 33%. Finally, a new 60,000 square foot building called the Siemens Healthineers Experience Center, will be added to North Carolina's Pearl, a 26-acre medical innovation district currently under construction. There is already a Siemens Healthineers Experience Center in Forchheim, Germany that offers access to test the company's portfolio of technology. "North Carolina is home to some of the leading research and innovation firms in the nation,' said North Carolina Governor Josh Stein. 'Siemens Healthineers' $141 million investment in the Pearl in Charlotte is the latest in a long line of companies that see the value of our well-trained workforce thanks to advanced health education programs in our state,' Stein added. Efforts to shore up US manufacturing capabilities come at a time when tariffs implemented by US President Donald Trump have made importing into the country less attractive. The ongoing trade war has brought instability to many industries, with healthcare being no exception. His sweeping tariffs have disrupted medical device supply chains globally. Levies placed on China have particularly impaired procurement channels with many components of devices made in the Asian country, such as semiconductors. Philips, for example, stated in its Q1 earnings report that it is bracing for a $340m hit due to tariffs. Siemens Healthineers is one of many companies redirecting resources to the US to make supply chains more robust. In April 2025, Thermo Fisher said it would spend $2bn to expand manufacturing in the US. Investments have been rife in pharma too, with Roche unveiling a $50bn investment strategy in the same month to upgrade three R&D sites in the US. Novartis, Johnson & Johnson and Eli Lilly have also made similar investment announcements. 'Our significant US employee base and broad portfolio of innovations are making vital contributions to the American healthcare system. With these new investments we're further demonstrating our long-term commitment and desire to grow along with the American economy,' Siemens Healthineers America's president and head John Kowal said. "Siemens Healthineers relocates Varian's Mexico manufacturing to the US" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
08-05-2025
- Business
- Yahoo
Siemens Healthineers AG (SMMNY) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ...
Q : Can you provide more color on the impact of tariffs, specifically the EUR0.15 impact you mentioned? A : The biggest impact is from imports into the US from Europe. The impact from the US into China is limited to selective parts of our portfolio, with some exemptions currently in place. The gross and net impact range is between EUR200 million and EUR300 million, with mitigation measures accounting for the EUR100 million delta. (Jochen Schmitz, CFO) The company had to lower the bottom end of its EPS outlook range due to new tariffs and a rapidly changing global trade environment. Siemens Healthineers AG ( SMMNY ) entered into its largest ever value partnership worth CAD800 million with the provincial government of Alberta, Canada, enhancing its position in cancer care. For the complete transcript of the earnings call, please refer to the full earnings call transcript . Story Continues Q: Regarding Varian, you previously guided for a margin improvement, but the first half performance was weaker. Can you explain the drivers and outlook for the second half? A: The first half was impacted by an unfavorable mix, particularly a high equipment share, which affected profitability. However, we expect margins to improve in the second half based on our backlog and anticipated shipments. (Jochen Schmitz, CFO) Q: Does the upper end of the EPS guidance range reflect any impact from tariffs? A: The upper end of EUR2.50 does not include tariff impacts. The midpoint of the new range, EUR2.35, reflects the EUR0.15 impact from tariffs. The upper range remains unchanged, depending on the success of mitigation measures. (Jochen Schmitz, CFO) Q: How is the situation evolving in China, particularly regarding orders and demand? A: The market remains on lower levels due to the anticorruption campaign, with no significant improvement in demand. The stimulus program and pent-up demand have not yet led to a visible market uptick. (Bernhard Montag, CEO) Q: Have the new Photon counting devices received FDA clearance, and how is the order intake expected to be impacted? A: We are pleased with the progress of Photon counting CT devices, which are generating strong interest. We do not see changes in customer demand, and we expect the equipment book-to-bill to remain above 1.1 for the full year. (Bernhard Montag, CEO) Q: Can you provide an update on the Atellica analyzer rollout and the impact of VBP in China? A: The Atellica franchise continues to grow above 20%, now comprising about 55% of CLS business revenues. In China, VBP impacts growth and margins, but the Atellica rollout is progressing well, contributing positively to margins. (Bernhard Montag, CEO) Q: How significant was the Alberta value partnership to the book-to-bill numbers, and what is the booking schedule over the contract's life? A: Without Alberta, the book-to-bill ratio would still be above 1. The partnership is an 8-year agreement, with significant volume expected initially, then spreading over time. (Jochen Schmitz, CFO) Q: Are you seeing any changes in pricing dynamics due to tariffs, and have you been able to pass on tariff surcharges to clients? A: We are cautious with pricing as a mitigation measure. While pricing can influence our guidance range, we manage it carefully to maintain market share and customer relationships. (Jochen Schmitz, CFO) For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Yahoo
01-05-2025
- Business
- Yahoo
More Impact, Together: Varian and Siemens Healthineers Portfolios Highlight More Impact, Innovations and More Breakthroughs Throughout Cancer Care Journey at ESTRO 2025
PALO ALTO, Calif., May 01, 2025--(BUSINESS WIRE)--Varian, a Siemens Healthineers company, will showcase an integrated portfolio designed to streamline workflows, and aiming to enhance patient experience and improve patient outcomes from screening to survivorship at the 2025 European Society for Radiotherapy and Oncology (ESTRO) annual meeting, May 2-6, in Vienna, Austria. "As part of Siemens Healthineers, we are uniquely positioned to transform cancer and beyond, and we are supercharging our commitment to patient-centricity with greater scale and impact," said Arthur Kaindl, Head of Varian. "Our accelerated pace of innovation demonstrates that we offer more impact, together, in our mission toward a world without fear of cancer." Varian and Siemens Healthineers will announce ground-breaking technologies empowering access to MRI for radiotherapy practices with the goal of establishing MRI in daily clinical routine, as well as showcase how its RapidArc Dynamic solution enables greater efficiency, precision, and flexibility in treatment planning and delivery at its booth (ESTRO #250), Friday, May 2, at 19:04 CEST. Varian's RapidArc Dynamic solution, available as an optional feature for the latest versions of Eclipse treatment planning software and the TrueBeam radiotherapy delivery platform, is powered by next-generation algorithms, combining a dynamic collimator and modulated ports working seamlessly in a single arc treatment field to provide clinicians with supreme control for optimal dose delivery. More innovations, together With the latest version of the ARIA CORE oncology management solution, Varian has strengthened integration with its software solutions, Noona and ARIA CORE Insights, to provide a seamless user experience and help streamline clinical workflows. Varian will also introduce ARIA CORE Automations, enabling users to automate workflows within ARIA CORE to drive efficiency and establish standardization. As an example of Varian and Siemens Healthineers' expanded strength as one team, Siemens Healthineers will be introducing Oncology Exchange, which improves integration by automatically transferring ARIA CORE prescription information to setup and configure the CT simulator. Reflecting the growing use of MRI in radiation therapy, Siemens Healthineers will present dedicated deep-learning algorithms for MRI autocontouring of brain metastases, and autocontouring of brain organs at risk – optimized for use with HyperArc high-definition radiotherapy. More breakthroughs, together With almost 40 Varian-supported abstracts accepted as part of ESTRO 2025, Varian is proud to collaborate with research leaders in the field. Included in this year's ESTRO program is evidence generated by Varian-sponsored clinical trials and consortium members underscoring the value of Varian's HyperSight imaging, an optional feature for selected Varian linacs, and Varian's Ethos adaptive radiotherapy system. "We recognize that every step of the cancer care journey needs to be effective and efficient, and delivered at the highest possible levels of clinical confidence and patient experience," Kaindl said. "We are committed to driving sustainable innovations that introduce new and enhanced tools in the fight against cancer." © 2025 VARIAN MEDICAL SYSTEMS, INC. All trademarks are the property of their respective owners. QR700022422 About Varian At Varian, a Siemens Healthineers company, we envision a world without fear of cancer. For more than 75 years, Varian has developed, built, and delivered innovative technologies and solutions that help care providers around the globe treat millions of patients each year. Today, as a Siemens Healthineers company, we support every step of the cancer care journey – from screening to survivorship. From advanced imaging and radiation therapy to comprehensive software and services, to interventional radiology, we are harnessing the power of our perspective while also pursuing clinical research to create a more efficient, and more personalized care pathway. Because, for cancer patients everywhere, their fight is our fight. For more information, visit View source version on Contacts Varian Press ContactKristin CoreyVarian Corporate Sign in to access your portfolio
Business Wire
01-05-2025
- Business
- Business Wire
More Impact, Together: Varian and Siemens Healthineers Portfolios Highlight More Impact, Innovations and More Breakthroughs Throughout Cancer Care Journey at ESTRO 2025
PALO ALTO, Calif.--(BUSINESS WIRE)--Varian, a Siemens Healthineers company, will showcase an integrated portfolio designed to streamline workflows, and aiming to enhance patient experience and improve patient outcomes from screening to survivorship at the 2025 European Society for Radiotherapy and Oncology (ESTRO) annual meeting, May 2-6, in Vienna, Austria. 'Our accelerated pace of innovation demonstrates that we offer more impact, together, in our mission toward a world without fear of cancer.' Share 'As part of Siemens Healthineers, we are uniquely positioned to transform cancer and beyond, and we are supercharging our commitment to patient-centricity with greater scale and impact,' said Arthur Kaindl, Head of Varian. 'Our accelerated pace of innovation demonstrates that we offer more impact, together, in our mission toward a world without fear of cancer.' Varian and Siemens Healthineers will announce ground-breaking technologies empowering access to MRI for radiotherapy practices with the goal of establishing MRI in daily clinical routine, as well as showcase how its RapidArc Dynamic solution enables greater efficiency, precision, and flexibility in treatment planning and delivery at its booth (ESTRO #250), Friday, May 2, at 19:04 CEST. Varian's RapidArc Dynamic solution, available as an optional feature for the latest versions of Eclipse treatment planning software and the TrueBeam radiotherapy delivery platform, is powered by next-generation algorithms, combining a dynamic collimator and modulated ports working seamlessly in a single arc treatment field to provide clinicians with supreme control for optimal dose delivery. More innovations, together With the latest version of the ARIA CORE oncology management solution, Varian has strengthened integration with its software solutions, Noona and ARIA CORE Insights, to provide a seamless user experience and help streamline clinical workflows. Varian will also introduce ARIA CORE Automations, enabling users to automate workflows within ARIA CORE to drive efficiency and establish standardization. As an example of Varian and Siemens Healthineers' expanded strength as one team, Siemens Healthineers will be introducing Oncology Exchange, which improves integration by automatically transferring ARIA CORE prescription information to setup and configure the CT simulator. Reflecting the growing use of MRI in radiation therapy, Siemens Healthineers will present dedicated deep-learning algorithms for MRI autocontouring of brain metastases, and autocontouring of brain organs at risk – optimized for use with HyperArc high-definition radiotherapy. More breakthroughs, together With almost 40 Varian-supported abstracts accepted as part of ESTRO 2025, Varian is proud to collaborate with research leaders in the field. Included in this year's ESTRO program is evidence generated by Varian-sponsored clinical trials and consortium members underscoring the value of Varian's HyperSight imaging, an optional feature for selected Varian linacs, and Varian's Ethos adaptive radiotherapy system. 'We recognize that every step of the cancer care journey needs to be effective and efficient, and delivered at the highest possible levels of clinical confidence and patient experience,' Kaindl said. 'We are committed to driving sustainable innovations that introduce new and enhanced tools in the fight against cancer.' © 2025 VARIAN MEDICAL SYSTEMS, INC. All trademarks are the property of their respective owners. QR700022422 About Varian At Varian, a Siemens Healthineers company, we envision a world without fear of cancer. For more than 75 years, Varian has developed, built, and delivered innovative technologies and solutions that help care providers around the globe treat millions of patients each year. Today, as a Siemens Healthineers company, we support every step of the cancer care journey – from screening to survivorship. From advanced imaging and radiation therapy to comprehensive software and services, to interventional radiology, we are harnessing the power of our perspective while also pursuing clinical research to create a more efficient, and more personalized care pathway. Because, for cancer patients everywhere, their fight is our fight. For more information, visit
